Research Triangle Institute & Eshelman School of Pharmacy
Why we need to deliver large amounts of powder to the lungs and the concurrent challenges
National Heart and Lung Institute (NHLI), Imperial College London & Royal Brompton Hospital
Implications for patient care and disease management
UKRI Rutherford Fellow, Medical Research Council Centre for Environment and Health, King's College London
Inhaled microplastics: an unrecognised health issue?
Elsevier
Winner of the Pat Burnell Young Investigator Award in 2014
Winning Conference Paper from DDL2014
Certara UK Limited
Winner of the Pat Burnell Young Investigator Award in 2015
Winning Conference Paper from 2015
Kiel University
Winner of the Pat Burnell Young Investigator Award 2010
Winning Conference Paper from 2010
Astrazeneca
The application of Precision Medicine and Genomics to enable new Respiratory medicines
Astrazeneca
Experimental evidence of regional lung deposition differences effecting the systemic exposure in dog
Professor of Pharmaceutics at the University of Hertfordshire
Computational and modelling approaches in dry powder inhaler product design
JDP Pharma Consulting
Classification of Inhaled Medicines: Development of an Inhalation-based Biopharmaceutical Classification System
King’s College London
Non-volatile Excipient effect on Inhaled Drug Product Performance
The University of Hong Kong
Inhalable mRNA dry powder formulation with PEGylated KL4 peptide delivery system
University of Algarve
In vitro behaviour of konjac glucomannan microparticles aimed at pulmonary tuberculosis therapy
Lung Health Research Centre, University of Melbourne
Inhaled Biologics for Respiratory Disorders
Nemera
Aerosol drug delivery through the mouth to target nasal cavities: RETRONOSE® concept
Nemera
Aerosol drug delivery through the mouth to target nasal cavities: RETRONOSE® concept
University of Coimbra
Designing lipid nanoparticles for intranasal delivery of antidepressants
